G. Daniel Grass MD, PhD
@gdgrass
Genitourinary Radiation Oncologist, Holman-trained @ Moffitt. Student of bladder and penile cancer. Trying to be a physician-scientist. Tweets=own
I often hear that post-TMT cystectomy is “fraught with complications even in experienced hands.” That hasn’t been my experience. With the right principles and disciplined technique, these cases can be remarkably straightforward. Maybe I’m delusional - but curious to hear what…
Radiation vs systemic therapy for isolated pelvic recurrence after cystectomy. @UroDocAsh moderates a debate between @AndreaNecchi @SanRaffaeleMI & Comron Hassanzadeh, MD, MPH @MDAndersonNews. Comron Hassanzadeh backs pelvic radiation for isolated recurrence, while Andrea Necchi…
Strong work @ninaobertopp & @MoffittNews Pilon-Thomas lab on how 8 Gy x 1 may open options for RT-cellular therapy integration! @MoffittRadOnc @RRS_RadRes @QuadShotNews Local Single-Dose Radiation Improves Adoptive Cell Therapy With Tumor-... sciencedirect.com/science/articl…
Cystectomy vs. Bladder Preservation: Weighing Options for Muscle-Invasive Bladder Cancer #MIBC. @BogdanaSchmidt @huntsmancancer & @mouwlab @DanaFarber join @UroDocAsh @MDAndersonNews in a debate on treatment options for muscle-invasive bladder cancer. #WatchNow on UroToday >…
Results from our Ph II multi-institutional study now out in @IJROBP redjournal.org/article/S0360-… Overall & objective responses noted in PD-L1 neg metastatic cervical ca with use of SBRT and atezo. Collaboration between @MoffittRadOnc @MoffittGYNONC @OhioStateRadOnc 🤝 @OncoAlert
Can PD-L1 negative cervical cancer respond to immunotherapy? At #ASCO25, Kamran Ahmed, MD, (@KAhmedMD) presents phase II results of SBRT + atezolizumab in metastatic cervical cancer, showing responses even in PD-L1 negative tumors. Read more: bit.ly/3HyjnOZ…
Excited to have been part of this landmark study of metastatic prostate cancer in U.S. Veterans! These findings affirm that precision oncology can be a powerful tool for advancing equity in cancer care. #CancerResearch #ProstateCancer
x.com/i/article/1923…
Honored to be recognized by the SUO with this prestigious award. Humbled to be amongst my esteemed predecessors. Much more to do in #bladdercancer @UroOnc @AmerUrological @BladderCancerUS @IBCG_BladderCA @MoffittGUOnc @MoffittNews
The SUO recognized Dr. Roger Li, MD, as the Young Investigator for the 2025 SUO at AUA Meeting. To see more about the award and prior winners, please visit suonet.org/awards/young-i…
Bladder preservation in muscle-invasive bladder cancer (MIBC) is evidence-based, patient-centered, and underutilized The latest @IBCG_BladderCA consensus in @EUplatinum offers global expert recommendations on when, how, and for whom bladder-sparing strategies are appropriate…
Big news from #SperosFlorida! Moffitt’s proton therapy system has arrived! This major milestone brings us one step closer to offering highly targeted cancer treatment to patients.
After a 4,600-mile journey from Belgium, our cyclotron has arrived at SPEROS FL. This robust accelerator will power Tampa Bay’s first proton therapy system, making Moffitt the region’s first health system to offer this advanced cancer treatment. Stay tuned tomorrow for the…
Using ROICellTrack on urothelial carcinoma, we identified distinct cancer-immune cell mixtures linked to transcriptomic & morphological signatures. Check out our recent paper with @song_xiaofei and @UrogerliMD. academic.oup.com/bioinformatics… #SpatialTranscriptomics
Received this letter today. Extremely honored to join this laser-focused group of clinicians/scientists/advocates that work tirelessly to eradicate #bladdercancer. Much to learn & much to do for our patients. Thank you @IBCG_BladderCA for the opportunity.
1/ Excited to share our new paper in @npjDigitalMed. We worked with @feiwang03 to develop a cutting-edge AI model 🖥️ that predicts response to neoadjuvant chemotherapy 💉 in patients with muscle-invasive #bladdercancer in the S1314 randomized clinical trial…
You are advancing the field of penile cancer patients around the globe through your pioneering research Jad. Could not be more honored and privileged to work together. Truly one of the greatest joys in my career! 👏👏👏
🚨 New Study Alert! 🚨 🔥 Our team @MoffittNews @MoffittGUOnc @SpiessPhilippe just published a single-cell analysis of the tumor microenvironment (TME) in penile squamous cell carcinoma (PSCC)! 📖 Read in Nature Scientific Reports: 🔗 nature.com/articles/s4159…
Excellent talk by Kenneth Gage MD, PhD dissecting the radiographic implications of PSMA-PET directed treatment decision making for the management of oligometastatic prostate cancer at GU ASCO 2025 in San Francisco @MoffittNews @MoffittRadOnc
Results from our phase II trial of brain MRI surveillance in stage IV breast cancer now out in @NeuroOnc academic.oup.com/neuro-oncology… By 6 months, about 25% of patients developed brain mets regardless of subtype @OncoAlert Thank you @FLBreastCancer for the support!
x.com/i/article/1885…
hot off the press - our @MoffittNews #multiD approach to #PAE in the setting of prostate cancer!! let’s go! 💪🏾💪🏾 @KOSJ12 @gdgrass @JulioPowSangMD @MoffittRadOnc @RishiA_MD #irad
Congratulations to Moffitt's Peter Johnstone, MD, for being awarded the @RadiumSociety Gold Medal this year! 🏅 This honor recognizes his outstanding contributions to oncology and exceptional service to the American Radium Society. Congratulations to Dr. Johnstone on an exciting…
‼️🚨The best current evidence on the role of HPV in Penile Cancer: A Meta-Analysis by our group @MoffittNews @SpiessPhilippe @AnnaGiuliano19 @CurtisPettaway1 @MajdAssaad @HPVRoundtable @hsafaMD @StopHPVCancer @HPVAction @MaHPVCoalition @FightHPVcancer doi.org/10.6004/jnccn.…
Great work led by @MoffittRadOnc star resident @VaseemKhatri assessing ADC T-DXd with SRS @QuadShotNews @PDBrownOnc @MoffittNews
Our multi institution series on T-DXd and SRS for HER2+ and HER2 Low Brain Mets was just published in @Nature_NPJ Breast Cancer! nature.com/articles/s4152…
🚨Out now @NatureMedicine🚨 Final results from #CORE2 combining IVe Creto+Nivo in cis-ineligible MIBC pts nature.com/articles/s4159… No DLTs pCR = 42.1% pCR assoc with baseline free E2F activity, TMB Increased T cell infiltration Formation of TLS assoc with pCR @MoffittNews